MAPK1 and ovarian carcinoma: Thus, EVs from ovarian cancer cells treated with cisplatin, but not untreated controls, are able to alter the phosphorylation state of key signaling proteins including downregulation of CREB, ERK2, and TOR phosphorylation with upregulation of JNK, p53, and p38 phosphorylation.